More than 38 million people in the U.S. are living with diabetes.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

A report from the human resources trade group SHRM, which just released its 2025 Benefits Survey—the most comprehensive ...

The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Weight loss injections promise quick results, but skipping blood screening can trigger serious risks like pancreatitis or ...

As weight-loss drugs like semaglutide and tirzepatide dominate global headlines, a new nationwide survey shows that 87 per cent of Indian adults beli ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...